Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending February 28, 2023
[Japanese GAAP]
January 12, 2023 | ||
Company name: | Hisamitsu Pharmaceutical Co., Inc. | |
Stock exchange listing: | Tokyo, Nagoya, Fukuoka | |
Securities code: | 4530 | |
URL: | https://global.hisamitsu/ | |
Representative: | NAKATOMI Kazuhide, President & CEO | |
Contact | MAEGAWA Yoshihiro, Department General Manager of Corporate Strategy Planning and Business | |
Development | ||
TEL: | +81-3-5293-1704 | |
Scheduled date of filing quarterly securities report: | Jan. 13, 2023 | |
Scheduled date of dividend payment: | ― | |
Preparation of supplementary materials for quarterly financial results: | Yes | |
Holding of quarterly financial results meeting: | Yes (for institutional investors and analysts, etc) |
(Amounts are rounded down to the nearest millions of yen)
1. Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending February 28, 2023 (March 1, 2022 to November 30, 2022)
(1) Consolidated Operating Results
Net sales | Operating profit | Ordinary profit | Profit attributable to | ||||||
owners of parent | |||||||||
Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | ||
Nine months ended Nov. 30, 2022 | 91,881 | 6.0 | 8,506 | 22.0 | 13,003 | 50.1 | 9,522 | 53.1 | |
Nine months ended Nov. 30, 2021 | 86,663 | 7.2 | 6,973 | 14.2 | 8,665 | 9.3 | 6,218 | 8.7 |
(Note) Comprehensive income: | Nine months ended Nov. 30, 2022 | 30,499 | millions of yen (226.2%) | |||
Nine months ended Nov. 30, 2021 | △ | |||||
9,349 millions of yen (36.2%) | ||||||
Profit per share | Diluted profit per | |||||
share | ||||||
yen | yen | |||||
Nine months ended Nov. 30, 2022 | 119.46 | 119.36 | ||||
Nine months ended Nov. 30, 2021 | 76.14 | 76.09 |
(Note) Beginning with the first quarter of the fiscal year ending on February 28, 2023, the Company has applied Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, March 31, 2020). All figures for the third quarter incorporate this accounting standard.
(2) Consolidated Financial Position
Total assets | Net assets | Shareholders' | |||
equity ratio | |||||
Millions of yen | Millions of yen | % | |||
As of Nov. 30, 2022 | 336,880 | 271,829 | 80.0 | ||
As of Feb. 28, 2022 | 302,858 | 254,885 | 83.5 | ||
(Reference) Shareholders' equity: | As of Nov. 30, 2022 | 269,504 millions of yen | |||
As of Feb. 28, 2022 | 252,914 millions of yen |
(Note) Beginning with the first quarter of the fiscal year ending on February 28, 2023, the Company has applied Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, March 31, 2020). All figures for the third quarter incorporate this accounting standard.
2. Dividends
Annual dividends | |||
First quarter | Second quarter | Third quarter | |
yen | yen | yen | |
Year ended Feb. 28, 2022 | ― | 42.00 | ― |
Year ending Feb. 28, 2023 | ― | 42.25 | ― |
Year ending Feb. 28, 2023 | |||
(Forecast) |
Fiscal year end
yen
42.00
42.25
Total
yen
84.00
84.50
(Note) 1.Revisions to the most recently announced dividends forecast: | No |
2. Breakdown of annual dividend forecast for the fiscal year 2023 |
84.00 yen
0.50 yen (A commemorative dividend for the 175th anniversary)
3. Consolidated Earnings Forecast for the Fiscal Year Ending February 28, 2023(March 1, 2022 to February 28, 2023)
(Percentages represent year-on-year changes) | |||||||||||
Net sales | Operating profit | Ordinary profit | Profit attributable to | Profit per share | |||||||
owners of parent | |||||||||||
Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | yen | |||
Full year | 123,000 | 2.3 | 11,100 | 18.9 | 12,700 | 0.5 | 9,700 | 0.4 | 121.68 | ||
(Note) 1.Revisions to the most recently announced consolidated forecast: | No |
2. Beginning with the first quarter of the fiscal year ending on February 28, 2023, the Company has applied Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, March 31, 2020). The above consolidated earnings forecast is prepared based on such accounting standards.
*Notes
-
Changes in significant subsidiaries during the period
(Chages in specified subsidiaries resulting in changes in scope of consolidation) - Apprication of special accounting methods for preparation of quarterly consolidated financial statements
- Changes in accounting policies, changes in accounting estimates, and restatement
- Changes in accounting policies due to revision of accounting standards
- Changes in accounting policies other than 1) above
- Changes in accounting estimates
- Restatement
- The number of shares outstanding (common stock)
- Total number of shares outstanding at the end of the period (including treasury stock)
As of Nov. 30, 2022 | : 85,164,895 shares |
As of Feb. 28, 2022 | : 85,164,895 shares |
2) Total number of treasury stock at the end of the period | |
As of Nov. 30, 2022 | : 5,665,543 shares |
As of Feb. 28, 2022 | : 5,427,284 shares |
3) Average number of shares outstanding during the period | |
Nine months ended Nov. 30, 2022 | : 79,715,046 shares |
Nine months ended Nov. 30, 2021 | : 81,670,294 shares |
- None
- Yes
- Yes
- None
- None
- None
*Quarterly financial results reports are not subjected to quarterly review.
*Explanation for appropriate use of financial forecasts and other special notes
Among this document, the forecasts based on the plan may changes due to uncertain factors. Therefore, the actual operating results may differ from the company's view.
Financial settlement briefings for institutional investors and analysts will be held on January 12, 2023. Presentation materials of financial results will be posted promptly on the company's website after the financial settlement briefings.
Quarterly Consolidated Financial Statements
(1) Quarterly Consolidated Balance sheets
(Millions of yen) | ||||||
Prior Fiscal Year End | Current Third Quarter | |||||
(As of Feb. 28, 2022) | (As of Nov. 30, 2022) | |||||
Assets | ||||||
Current assets | ||||||
Cash and deposits | 129,290 | 133,994 | ||||
Notes and accounts receivable - trade | 38,505 | ― | ||||
Notes and accounts receivable - trade, and contract assets | ― | 37,775 | ||||
Securities | 13,141 | 15,501 | ||||
Merchandise and finished goods | 8,919 | 11,480 | ||||
Work in process | 438 | 670 | ||||
Raw materials and supplies | 7,055 | 8,156 | ||||
Other | 3,219 | 11,870 | ||||
Allowance for doubtful accounts | 393 | 297 | ||||
200,176 | ||||||
Total current assets | △ | △ | ||||
Non-current assets | ||||||
Property, plant and equipment | ||||||
Buildings and structures, net | 13,905 | 14,179 | ||||
Other, net | 25,163 | 30,273 | ||||
Total property, plant and equipment | 39,069 | 44,453 | ||||
Intangible assets | ||||||
Sales rights | 442 | 406 | ||||
Other | 883 | 729 | ||||
Total intangible assets | 1,326 | 1,136 | ||||
Investments and other assets | ||||||
Investment securities | 52,519 | 61,728 | ||||
Other | 9,980 | 10,619 | ||||
Allowance for doubtful accounts | 214 | 207 | ||||
62,286 | ||||||
Total investments and other assets | △ | △ | ||||
Total non-current assets | 102,681 | 117,730 | ||||
Total assets | 302,858 | 336,880 |
(Millions of yen) | |||
Prior Fiscal Year End | Current Third Quarter | ||
(As of Feb. 28, 2022) | (As of Nov. 30, 2022) | ||
Liabilities | |||
Current liabilities | |||
Notes and accounts payable - trade | 7,533 | 10,334 | |
Electronically recorded obligations - operating | 5,692 | 6,369 | |
Short-term loans payable | 1,071 | 1,071 | |
Income taxes payable | 2,938 | 2,073 | |
Provision for sales returns | 135 | ― | |
Provision for bonuses | 1,363 | 530 | |
Other | 13,424 | 31,105 | |
Total current liabilities | 32,160 | 51,485 | |
Non-current liabilities | |||
Long-term loans payable | 219 | 166 | |
Net defined benefit liability | 8,216 | 8,508 | |
Other | 7,376 | 4,891 | |
Total non-current liabilities | 15,812 | 13,566 | |
Total liabilities | 47,972 | 65,051 | |
Net assets | |||
Shareholders' equity | |||
Capital stock | 8,473 | 8,473 | |
Capital surplus | 2,356 | 2,361 | |
Retained earnings | 236,192 | 233,111 | |
Treasury shares | 19,527 | 20,419 | |
Total shareholders' equity | 227,495 | 223,527 | |
△ | △ | ||
Accumulated other comprehensive income | |||
Valuation difference on available-for-sale securities | 15,070 | 17,953 | |
Revaluation reserve for land | 3,641 | 3,616 | |
Foreign currency translation adjustment | 5,633 | 23,558 | |
Remeasurements of defined benefit plans | 1,073 | 847 | |
Total accumulated other comprehensive income | 25,419 | 45,976 | |
Share acquisition rights | 254 | 250 | |
Non-controlling interests | 1,717 | 2,074 | |
Total net assets | 254,885 | 271,829 | |
Total liabilities and net assets | 302,858 | 336,880 |
- Quarterly Consolidated Statements of Income and Comprehensive Income
Quarterly Consolidated Statements of Income
(Millions of yen) | |||
Prior Fiscal Year | Current Fiscal Year | ||
(Mar. 1, 2021 - Nov. 30, 2021) | (Mar. 1, 2022 - Nov. 30, 2022) | ||
Net sales | 86,663 | 91,881 | |
Cost of sales | 34,884 | 39,100 | |
Gross profit | 51,779 | 52,781 | |
Selling, general and administrative expenses | 44,805 | 44,274 | |
Operating profit | 6,973 | 8,506 | |
Non-operating income | |||
Interest income | 110 | 398 | |
Dividend income | 595 | 626 | |
Foreign exchange gains | 891 | 3,210 | |
Other | 329 | 452 | |
Total non-operating income | 1,927 | 4,687 | |
Non-operating expenses | |||
Interest expenses | 11 | 12 | |
Share of loss of entities accounted for using equity method | 74 | 35 | |
Cost for idle operation | 77 | 95 | |
Other | 72 | 46 | |
Total non-operating expenses | 235 | 189 | |
Ordinary profit | 8,665 | 13,003 | |
Extraordinary income | |||
Gain on disposal of non-current assets | 6 | 142 | |
Gain on sales of investment securities | 652 | ― | |
Total extraordinary income | 659 | 142 | |
Extraordinary losses | |||
Loss on disposal of non-current assets | 53 | 116 | |
Loss on discontinuation of sale | 279 | ― | |
Total extraordinary losses | 333 | 116 | |
Profit before income taxes | 8,992 | 13,029 | |
Income taxes | 2,564 | 3,208 | |
Profit | 6,427 | 9,821 | |
Profit attributable to non-controlling interests | 209 | 299 | |
Profit attributable to owners of parent | 6,218 | 9,522 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Hisamitsu Pharmaceutical Co. Ltd. published this content on 12 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 January 2023 06:19:11 UTC.